Possia
ticagrelor
Table of contents
Overview
The marketing authorisation for Possia has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Possia
|
| Agency product number |
EMEA/H/C/002303
|
| Active substance |
ticagrelor
|
| International non-proprietary name (INN) or common name |
ticagrelor
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
B01AC24
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
AstraZeneca AB
|
| Revision |
2
|
| Date of issue of marketing authorisation valid throughout the European Union |
03/12/2010
|
| Contact address |
Gärtunavägen
151 85 Södertälje Sweden |
Product information
24/10/2012 Possia - EMEA/H/C/002303 - WS/0292
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).